Concepedia

Upstream Bioprocess Development

Upstream Bioprocess Development is a strategic phase within biopharmaceutical manufacturing that encompasses the design, optimization, and scale-up of cell culture processes—particularly in single-use bioreactors—for the production of monoclonal antibodies, distinguishing itself from downstream activities by focusing on the biological and physiological aspects of product generation prior to purification.

22

Publications

764

Citations

83

Authors

39

Institutions

Publications per year

2017–2026

11

Parents

Publications

22

Moving towards an era of hybrid modelling: advantages and challenges of coupling mechanistic and data-driven models for upstream pharmaceutical bioprocesses

Apostolos Tsopanoglou, Ioscani Jiménez del Val · Current Opinion in Chemical Engineering · 2021 · 99 citations · Full text

, , +17

From gene to harvest: insights into upstream process development for the <scp>GMP</scp> production of a monoclonal antibody in transgenic tobacco plants

M. Sack, Thomas W. Rademacher, Holger Spiegel et al. · Plant Biotechnology Journal · 2015 · 99 citations · Full text

, , +17

Efficient high‐throughput biological process characterization: Definitive screening design with the Ambr250 bioreactor system

Mitchell Tai, Amanda Ly, Inne Leung et al. · Biotechnology Progress · 2015 · 65 citations

, , +16

Intensified design of experiments for upstream bioreactors

Moritz von Stosch, Mark J. Willis · Engineering in Life Sciences · 2016 · 60 citations · Full text

, , +17

High-throughput microbioreactor provides a capable tool for early stage bioprocess development

Mathias Fink, Monika Cserjan‐Puschmann, Daniela Reinisch et al. · Scientific Reports · 2021 · 50 citations · Full text

, , +15

1–5 of 22

Authors

83

  1. MV
    Moritz von Stosch

    Newcastle University, United Kingdom

    3 publications · 108 citations

    3

    h-index

  2. KM
    Katerina Michailidi

    University of Patras, Greece

    1 publications · 29 citations

    1

    h-index

  3. VC
    Véronique Chotteau

    KTH Royal Institute of Technology, Sweden

    1 publications · 14 citations

    1

    h-index

  4. IK
    Ioannis K. Kookos

    University of Patras, Greece

    1 publications · 29 citations

    1

    h-index

  5. MT
    Mitchell Tai

    Massachusetts Institute of Technology, United States

    1 publications · 65 citations

    1

    h-index

1–5 of 83

Institutions

39

  1. Newcastle University

    Newcastle upon Tyne, United Kingdom

    2 h-index

    3 publications

    156 citations

  2. BOKU University

    Vienna, Austria

    2 h-index

    4 publications

    249 citations

  3. Bristol-Myers Squibb (United States)

    New York, United States

    2 h-index

    9 publications

    425 citations

  4. TU Wien

    Vienna, Austria

    1 h-index

    2 publications

    54 citations

  5. Bayer (United States)

    Whippany, United States

    1 h-index

    1 publications

    11 citations

  6. University of New Hampshire at Manchester

    Manchester, United States

    1 h-index

    1 publications

    12 citations

  7. University of Maryland, Baltimore County

    Baltimore, United States

    1 h-index

    2 publications

    40 citations

  8. GlaxoSmithKline (Switzerland)

    Bern, Switzerland

    1 h-index

    3 publications

    36 citations

1–8 of 39

Venues

  1. Biotechnology Progress

    4 publications · 148 citations

    4

    h-index

  2. Engineering in Life Sciences

    2 publications · 71 citations

    2

    h-index

  3. Biotechnology and Bioengineering

    1 publications · 14 citations

    1

    h-index

  4. 1

    h-index

  5. BioProcessing Journal

    1 publications · 18 citations

    1

    h-index

1–5